Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
ID: 357004Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357004

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-25-205.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Stimulating Hematology Investigation: New Endeavors (SHINE)" aimed at promoting innovative research in non-malignant hematology. This initiative invites investigator-initiated research project grant applications (R01) that focus on basic and early translational hematology research, with a particular emphasis on fostering diverse perspectives within research teams through a required Plan for Enhancing Diverse Perspectives (PEDP). Approximately $2.5 million is available for 5-8 awards, with applications due by February 5, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAS-25-205-Full-Announcement.html
    Please provide the text you would like summarized.
    PAS-25-205.html
    The National Institutes of Health (NIH) is issuing a Notice of Funding Opportunity (NOFO) titled "Stimulating Hematology Investigation: New Endeavors (SHINE)," promoting research in non-malignant hematology relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Heart, Lung, and Blood Institute. This initiative invites investigator-initiated research project grant applications (R01) focusing on innovative areas within basic and early translational hematology research. Key components of the funding include the requirement for a Plan for Enhancing Diverse Perspectives (PEDP), aimed at fostering inclusivity within research teams. Approximately $2.5 million is allocated for 5-8 awards, with applications due by February 5, 2025, for new projects. Applicants must comply with specific registration processes, and proposals will be evaluated based on scientific merit, innovation, rigor, investigator expertise, and the effectiveness of diversity plans. The SHINE program's dynamic nature allows for evolving research topics, responding to emerging questions within the hematology field, guided by workshops and public meetings. Overall, this NOFO emphasizes NIH’s commitment to innovative research and inclusivity in the scientific community.
    Similar Opportunities
    Cooperative Centers of Excellence in Hematology (CCEHs)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Cooperative Centers of Excellence in Hematology (CCEHs)" aimed at enhancing the nonmalignant hematology research community through a national network of resources and services. This program seeks to provide state-of-the-art expertise, enrichment activities, and small pilot funding to improve the quality and transparency of hematology research. With an estimated total program funding of $3,745,000 and the expectation of awarding five grants, interested applicants can reach out to Jennifer Norton at jenna.norton@nih.gov or by phone at 301-402-5496 for further details. The application process is set to begin with a synopsis posting on April 1, 2026, and will close on July 10, 2026, with awards anticipated by January 30, 2027.
    Notice of Intent to Publish a Funding Opportunity Announcement for Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the continuation of the NIDDK Hematology Central Coordinating Center (HCC) under a cooperative agreement. The HCC will collaborate with up to five Cooperative Centers of Excellence in Hematology (CCEH) to provide administrative support, develop communication strategies, and implement educational programs aimed at enhancing research in nonmalignant hematology. This initiative is crucial for fostering a national multidisciplinary research effort to study hematopoiesis and address nonmalignant hematologic diseases. The estimated total program funding is $1 million, with a single award anticipated, and the NOFO is expected to be published in December 2024, with applications due by March 2025. For further details, potential applicants should prepare to submit their proposals in alignment with the requirements outlined in the forthcoming NOFO.
    Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a federal grant opportunity titled "Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)." This program aims to support educational activities that enhance the diversity of the biomedical, behavioral, and clinical research workforce by providing research experiences and related opportunities for individuals from underrepresented groups. The initiative is crucial for addressing health disparities in cardiovascular, pulmonary, and hematologic diseases by fostering a diverse scientific workforce. Interested applicants can apply for funding up to $175,000 per year for a maximum of five years, with applications opening on December 29, 2023, and a submission deadline of August 19, 2026. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-25-001.html.
    Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional)." This initiative aims to support new investigators from diverse and underrepresented backgrounds in biomedical research, enabling them to conduct small-scale projects that align with the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and other participating institutes. The grants, with a maximum budget of $125,000 per year for a project period not exceeding three years, are intended to facilitate the transition of these researchers toward independence while addressing health disparities. Interested applicants must demonstrate that they have had less than $125,000 in direct costs from combined active research funding and can submit proposals starting in early 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-097.html.
    Role of HIV Infection and Chronic Inflammation in Clonal Hematopoiesis
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) focused on the role of HIV infection and chronic inflammation in clonal hematopoiesis (CH), particularly clonal hematopoiesis of indeterminate potential (CHIP). The initiative aims to investigate the mechanisms by which chronic inflammation and HIV-related factors contribute to CHIP, as well as its prevalence among individuals with HIV and other chronic conditions, with the ultimate goal of developing innovative diagnostic and therapeutic strategies for heart, lung, blood, and sleep (HLBS) health. While applications are not currently being solicited, potential applicants are encouraged to begin forming collaborations and project proposals in anticipation of the funding opportunity, which is expected to open in April 2026, with an estimated award date in October 2026. For further inquiries, interested parties can contact the Division of Blood Diseases and Resources at nhlbidbdrgrantresource@nhlbi.nih.gov.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Supporting Talented Early Career Researchers in Genomics," aimed at supporting innovative research projects led by Early Stage Investigators (ESIs) with a focus on genomics. This initiative encourages diverse applicants to propose research that aligns with the mission of the National Human Genome Research Institute (NHGRI), covering areas such as genomic sciences, genomic medicine, genomic data science, and the ethical implications of genomics. The program has a funding commitment of at least $2 million, with plans to award 3-5 grants, each with an annual budget cap of $400,000. Applications must be submitted electronically by February 26, 2027, and should include a detailed professional development plan and a resource sharing plan in compliance with NIH policies. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Opportunities for New and 'At-Risk' Investigators to Promote Workforce Diversity," aimed at enhancing diversity within the biomedical research workforce. This initiative invites R01 grant applications for independent research projects that align with the scientific missions of participating NIH Institutes or Centers, specifically targeting New Investigators and At-Risk Investigators from underrepresented backgrounds, including racial and ethnic minorities and individuals with disabilities. The program underscores the significance of diverse perspectives in addressing health disparities and aims to strengthen the research pipeline while fostering innovative solutions to public health challenges. Interested applicants can find more information and guidelines at the NIH grants website, with applications due by November 5, 2027. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Generate A Precision Medicine Intergenerational Resource for the Study of Factor VIII Immunogenicity in Severe Hemophilia A:Clinical Coordinating Center
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the establishment of a Clinical Coordinating Center aimed at generating a Precision Medicine Intergenerational Resource for studying Factor VIII immunogenicity in severe Hemophilia A. This initiative will utilize a UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement, providing a total funding ceiling of $1,338,000 over a potential seven-year period, contingent upon the successful completion of defined milestones. The project is critical for advancing research in hemophilia treatment and will involve a collaborative effort with a companion award for a Biospecimen and Data Resource Center. Interested applicants can reach out to Iman K. Martin, PhD, MPH, MS at iman.martin@nih.gov or call 301-435-0065 for further details, with the estimated synopsis post date having been set for March 2, 2020.